View in EDS

Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.

Saved in:
Bibliographic Details
Title: Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Authors: Santoni-Rugiu, Eric1 eric.santoni-rugiu.02@regionh.dk, Grauslund, Morten1 morten.grauslund@skane.se, Melchior, Linea C.1 linea.cecilie.melchior@regionh.dk, Costa, Junia C.2 junia.cardoso.costa@regionh.dk, Sørensen, Jens B.3 jens.benn.soerensen@regionh.dk, Urbanska, Edyta M.3 edyta.maria.urbanska@regionh.dk
Source: Lung Cancer (01695002). Nov2017, Vol. 113, p14-17. 4p.
Database: Academic Search Ultimate
Description
ISSN:01695002
DOI:10.1016/j.lungcan.2017.08.024